“Long-term Safety and Efficacy Extension Trial of Bimatoprost SR”
This study will evaluate the long-term safety and efficacy of Bimatoprost SR in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR.
Drug - Bimatoprost SR
Patients from Stage 2 of lead-in studies 093/095 are eligible to receive up to 2 additional Bimatoprost SR administrations of the same dose in the study eye through completion of Month 12 visit. Patients from lead-in studies 091/092 will not receive additional Bimatoprost SR administrations in the study eye. Fellow eye of all patients will receive only standard of care based on the investigator's judgment
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With Open Angle Glaucoma or Ocular Hypertension